Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease.
Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease.
复制标题
DOI：
10.1016/j.yexmp.2013.01.002
复制
发表时间：
2013-04
影响因子：
3.6
通讯作者：
Keene, C. Dirk
中科院分区：
文献类型：
--
作者：
Cimino, Patrick J.;Yang, Yue;Li, Xianwu;Hemingway, Jake F.;Cherne, Makenzie K.;Khademi, Shawn B.;Fukui, Yoshinori;Montine, Kathleen S.;Montine, Thomas J.;Keene, C. Dirk
Alzheimer’s disease (AD) neuropathology is characterized by innate immune activation primarily through prostaglandin E2 (PGE2) signaling. Dedicator of cytokinesis 2 (DOCK2) is a guanyl nucleotide exchange factor expressed exclusively in microglia in the brain and is regulated by PGE2 receptor EP2. DOCK2 modulates microglia cytokine secretion, phagocytosis, and paracrine neurotoxicity. EP2 ablation in experimental AD results in reduced oxidative damage and amyloid beta (Aβ) burden. This discovery led us to hypothesize that genetic ablation of DOCK2 would replicate the anti-Aβ effects of loss of EP2 in experimental AD. To test this hypothesis, we crossed mice that lacked DOCK2 (DOCK2−/−), were hemizygous for DOCK2 (DOCK2+/−), or that expressed two DOCK2 genes (DOCK2+/+) with APPswe-PS1Δe9 mice (a model of AD). While we found no DOCK2-dependent differences in cortex or in hippocampal microglia density or morphology in APPswe-PS1Δe9 mice, cerebral cortical and hippocampal Aβ plaque area and size were significantly reduced in 10-month-old APPswe-PS1Δe9/DOCK2−/− mice compared with APPswe-PS1Δe9/DOCK2+/+ controls. DOCK2 hemizygous APPswe-PS1Δe9 mice had intermediate Aβ plaque levels. Interestingly, soluble Aβ42 was not significantly different among the three genotypes, suggesting the effects were mediated specifically in fibrillar Aβ. In combination with earlier cell culture results, our in vivo results presented here suggest DOCK2 contributes to Aβ plaque burden via regulation of microglial innate immune function and may represent a novel therapeutic target for AD.
登录
查看更多内容
DOI：
10.1126/science.1170179
发表时间：
2009-04-17
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Nishikimi A;Fukuhara H;Su W;Hongu T;Takasuga S;Mihara H;Cao Q;Sanematsu F;Kanai M;Hasegawa H;Tanaka Y;Shibasaki M;Kanaho Y;Sasaki T;Frohman MA;Fukui Y
通讯作者：
Fukui Y
影响因子：
5.3
作者：
Hickman, Suzanne E.;Allison, Elizabeth K.;El Khoury, Joseph
通讯作者：
El Khoury, Joseph
DOI：
10.1196/annals.1332.005
发表时间：
2004-01-01
期刊：
PROTECTIVE STRATEGIES FOR NEURODEGENERATIVE DISEASES
影响因子：
--
作者：
Cole, GM;Morihara, T;Frautschy, SA
通讯作者：
Frautschy, SA
DOI：
10.1084/jem.20091776
发表时间：
2010-04-12
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Gotoh K;Tanaka Y;Nishikimi A;Nakamura R;Yamada H;Maeda N;Ishikawa T;Hoshino K;Uruno T;Cao Q;Higashi S;Kawaguchi Y;Enjoji M;Takayanagi R;Kaisho T;Yoshikai Y;Fukui Y
通讯作者：
Fukui Y
影响因子：
5.4
作者：
Lei, Yu;Liu, Cunlan;Takahama, Yousuke
通讯作者：
Takahama, Yousuke